Important Update to Visitor Policy. Please read important information about COVID-19 vaccination requirements or testing for some visitors. Read our visitor policy.
Jedd D. Wolchok, MD, PhD, FASCO
Medical Oncologist
Titles
Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation; Chief, Immuno-Oncology Service, HOPP; Director, Parker Institute for Cancer Immunotherapy at MSK; Associate Director, Ludwig Center for Cancer Immunotherapy
Dr. Wolchok accepts the following list of insurance providers. Select your insurance provider to see more details.
Aetna
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Blue Distinction Center
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
Health Insurance Exchanges
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
CIGNA
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
If you are a New York State resident: Please ask your insurance if you need a one-time referral.
If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
EmblemHealth (including GHI, HIP, ConnectiCare, and Vytra)
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Empire Blue Cross Blue Shield
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
HealthFirst
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
HealthSmart
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Horizon Blue Cross Blue Shield of New Jersey
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Humana
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Interlink Health Services
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Lifetrac
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
MagnaCare
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
Medicare & Medicaid
For information about Medicare and Medicaid, please visit this page
Multiplan/Beech Street/PHCS
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
Multiple Insurance Plans
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
MVP
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
New York State Employee Health Insurance Plan (Empire Plan)
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Oscar
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Other Blue Cross Blue Shield plans
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
Other Coverage Options
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
AXA Assistance USA
Beech Street
Integrated Health Plans
National Health Administrators
National Preferred Provider Network
UnitedHealthcare's Cancer Resource Services
United Resource Network
Veterans Choice Program
Oxford
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
TRICARE
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
UnitedHealthcare
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
Internal Medicine - New York University Medical Center/Bellevue Hospital
Fellowships
Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center
Board Certifications
Internal Medicine, Medical Oncology
I am a medical oncologist who specializes in the treatment of melanoma. My research is focused on the development of innovative ways to use the immune system to treat cancer. I have been at the forefront of cancer immunotherapy, as an active physician scientist and as a principal investigator in several pivotal clinical trials, including one that led to the US Food and Drug Administration approval of ipilimumab and nivolumab for patients with advanced melanoma. I also direct a translational research laboratory focused on next-generation immunotherapies and combinations.
Read more
Ipilimumab was the first drug ever shown to improve survival in these patients. It has fundamentally changed this disease’s outcome — people who were once given a matter of months are living years longer in some cases. A number of patients I treated with ipilimumab in 2004 are still alive and free of cancer today. As a physician, nothing is more gratifying than being able to give someone his or her life back after cancer.
Despite the successes of ipilimumab, only about 20 percent of melanoma patients respond to the drug. This experience led me to test ipilimumab in combination with another immune drug, called nivolumab. I designed and led the phase I, II, and III clinical trials that led to the FDA approval of this combination in 2015 for advanced melanoma. You can hear about one patient’s experience with this combination here.
In 2011, I established the Immunotherapeutics Clinical Core, a specialized phase I outpatient unit at MSK that conducts novel immunotherapy trials, with a specific emphasis on identifying molecular biomarkers that can predict response. This group treats patients with a variety of cancers and has become a model for similar efforts by other major cancer centers throughout the world.
I received my undergraduate degree from Princeton University and my MD and PhD degrees from New York University, where I also fulfilled my residency program. After completing my fellowship at MSK, I remained on the faculty as part of the Melanoma and Immunotherapeutics Service. I am also a professor of medicine at Weill Cornell Medical College.
Awards and Honors
David Karnofsky Award, American Society of Clinical Oncology (ASCO, 2022)
AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research (2020)
ESMO Award for Immuno-Oncology (2020)
2019 Distinguished Alumnus of the Year Award @MSK
Kersey Lecture- University of Minnesota (2019)
Fellow of the American Society of Clinical Oncology (FASCO) (2018)
TAT Honorary Awardee (2017)
Society of Surgical Oncology Ewing Lecture (2017)
RCCS Monsey Medical Devotion Award (2017)
Alfred Taubman Prize for Excellence in Translational Medical Research, Univ of Michigan (2016)
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Visit PubMed for a full listing of Dr. Wolchok’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jedd D. Wolchok discloses the following relationships and financial interests:
Amgen Provision of Services (uncompensated)
Apricity Health Ownership / Equity Interests; Provision of Services
Arsenal IO Canada Parent, Inc. Ownership / Equity Interests; Provision of Services
Ascentage Pharma Ownership / Equity Interests; Provision of Services
Astellas Provision of Services (uncompensated)
AstraZeneca Provision of Services (uncompensated)
BeiGene, Ltd. Ownership / Equity Interests; Provision of Services
Bicara Therapeutics, Inc. Provision of Services
Boehringer Ingelheim Provision of Services (uncompensated)
Bristol-Myers Squibb Provision of Services
Chugai Pharmaceuticals Provision of Services (uncompensated)
Daiichi Sankyo Provision of Services
Dragonfly Therapeutics, Inc. Provision of Services (uncompensated)
Georgiamune, LLC Provision of Services (uncompensated)
Idera Pharmaceuticals, Inc. Provision of Services (uncompensated)
Merck & Co Inc. Intellectual Property Rights; Provision of Services (uncompensated)
Merial Limited Intellectual Property Rights
PsiOxus Therapeutics Ltd Provision of Services (uncompensated)
Recepta Biopharma S.A. Provision of Services (uncompensated)
Sellas Life Science Group Provision of Services
Surface Oncology Provision of Services
Tizona Therapeutics Ownership / Equity Interests; Provision of Services
Trieza Pharmaceuticals, Inc. Ownership / Equity Interests
Trishula Therapeutics, Inc. Provision of Services
Werewolf Therapeutics, Inc. Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.
